Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Celecoxib added to first-line docetaxel/carboplatin for advanced ovarian cancer
NL-OMON23637Phase 2Active, not recruiting
- Sponsor
- Sanofi
- Start
- Oct 2002
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised trial of celecoxib in ovarian cancer, fallopian tube cancer (PFTC) and primary peritoneal cancer (PPC) (2 arms), sponsored by Sanofi. Primary endpoints: Response rate and Progression-free survival. Started Oct 2002; status: active, not recruiting.
02
Drugs
celecoxib
03
Conditions
ovarian cancerfallopian tube cancer (PFTC)primary peritoneal cancer (PPC)
Beyond the preview
Go deeper on NL-OMON23637.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON23637.